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Morpholino Oligos: Making Sense of Antisense?
Janet Heasman1
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Since morpholino oligos were first introduced as a means to inhibit gene function in embryos, in the Spring of 2000, they
have been tested in a range of model organisms, including sea urchin, ascidian, zebrafish, frog, chick, and mouse. This
review surveys the results of these studies and examines the successes and limitations of the approach for targeting maternal
and zygotic gene function. The evidence so far suggests that, with careful controls, morpholinos provide a relatively simple
and rapid method to study gene function. © 2002 Elsevier Science (USA)
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The demand for knockout technology in developmental
biology is rising exponentially as genes of interest emerge at
an ever-increasing rate from genomic studies, and therefore
the central task becomes to relate genes to functions.
Historically, lengthy mutant screens in Drosophila, and
Caenorhabditis elegans have provided us with most of our
knowledge of gene function in development, but reverse
genetic approaches have become increasingly attractive,
because they offer the possibility of taking interesting
candidate genes from genomic databases and speedily iden-
tifying their roles.
Against this background, it is not surprising that the
introduction of a new loss-of-function technology has been
met with enthusiasm by developmental biologists. Mor-
pholino antisense oligos were first developed for clinical
therapeutic applications, where previous antisense ap-
proaches had proven seriously flawed (Summerton and
Weller, 1997). They were first introduced into developmen-
tal biology early in 2000 (Heasman et al., 2000) and have
since been used by researchers in a range of model organ-
isms, including sea urchin (Howard et al., 2001), Ciona
savignyi (Satou et al., 2001), Xenopus laevis (Audic et al.,
2001; Schweickert et al., 2001; Sumanas et al., 2001),
Xenopus tropicalis (Nutt et al., 2001), zebrafish (Nasevicius
and Ekker, 2000; Bauer et al., 2001; Ross et al., 2001;1 Fax: (513) 636-4317. E-mail: heabq9@chmcc.org.
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and 19 papers in Genesis 30, July 30, 2001), chick (Kos et al.,
2001), and mouse (Coonrod et al., 2001). In the summer of
2001, an entire issue of the journal “Genesis” was dedicated
to articles studying gene function in development using
this technique. As the first wave of usage is well underway,
the aim of this review is to survey the successes and
limitations of this latest loss-of-function tool.
Morpholino Oligos Block Messenger mRNA
Translation
First generation antisense oligos were designed as short
stretches of DNA (18–22 mers) that form RNA–DNA
hybrids with the target mRNA and act as substrates for
RNAse H to degrade the mRNA (Cazenave et al., 1989). The
target mRNA is cleaved by RNAse H, and the fragments are
subsequently broken down by nuclease activity. DNA oli-
gos have had very limited applicability in developmental
studies, both because they have nonspecific toxic side
effects, (Heasman et al., 1991) and because degraded
mRNAs are continually replaced by new transcription,
making continued treatment with oligo a necessity. The
one exception to this general case is that of loss-of-function
studies of maternal genes in Xenopus embryos (Zuck et al.,
1998). Here, antisense oligos are injected into the oocyte,
which is then cultured for several days before fertilization.
The oligos degrade the target mRNA, and are themselves
broken down, so that they have no toxic effect on the
209
embryos after fertilization. This, together with the fact that
there is no transcription in the developing Xenopus embryo
until the 4000-cell stage, makes DNA oligos a feasible
approach for functional analysis in this restricted area
(Heasman et al., 1994; Zhang et al., 1998).
Morpholino oligos were designed specifically to over-
come many of the limitations of regular DNA oligos (Gene
Tools, LLC). Recognizing that RNAse H-mediated degrada-
tion was not the only efficient way to prevent translation,
Summerton and Weller (1997) developed a DNA analog that
acts by blocking translation. This analog has the riboside
moiety of each subunit converted to a morpholine moiety
(morpholine  C4H9NO), and uses a phosphorodiamidate
intersubunit linkage instead of phosphorodiester linkages
(see Summerton and Weller, 1997 for a detailed descrip-
tion). Morpholino oligos only block translation when they
are designed to be complementary to the 5 leader se-
quences, or to the first 25 bases 3 to the AUG translational
start site, and it is presumed that they act by preventing
ribosomes from binding. In cell-free translation experi-
ments, they were shown to have greater efficiency and
specificity than other antisense oligos, and tests showed
excellent solubility and stability characteristics (Summer-
ton, 1999). Because the 5UTR is less conserved than coding
regions, the chance of the morpholino oligo blocking incor-
rect mRNAs nonspecifically is less than for traditional
oligos. Their increased specificity also derives from the fact
that translation is not blocked when there are several
mismatched nucleotides. For most effective RNA target-
ing, oligos are recommended to be 25 mers in length, and
have little self-complementarity (four or fewer contiguous
intrastand base pairs). Water solubility is maintained by
using less than 36% guanine content and no runs of more
than triplets of GGG (Gene Tools, LLC).
The next critical phase for the development of morpho-
lino oligos as loss-of-function tools in developmental stud-
ies has been to test them in embryos.
Morpholino Injections Phenocopy Known Mutants
The critical questions to answer for testing morpholino
oligos’ reliability as loss-of-function tools are, first, whether
they mimic the phenotypes of known mutants, and if so,
how reproducible or penetrant the effects are. Of equal
importance in the development of morpholinos as tools to
study novel gene function is to recognize toxic side effects
of oligo injection, to avoid the trap of confusing those
effects with those caused by true loss-of-function. A third
important consideration in deciding whether morpholinos
could be useful in studying genes acting during organogen-
esis is how long after injection they actively block transla-
tion.
Most published work to date testing morpholinos has
been carried out on zebrafish embryos, where many mu-
tants are available that have defined the roles of genes
important for development. In fish embryos, oligos are
typically injected at the one- to four-cell stage into the
cytoplasm or yolk. Table 1 is a partial list of the genes that
have been studied by their loss-of-function both in mutants
and in morpholino-injected embryos. Clearly, this repre-
sents the most positive view of the success of the morpho-
lino approach since injections which do not phenocopy
mutants are much less likely to be published. However, in
two papers, the success rate of tested genes was reported.
Lele et al. (2000) report a 100% success rate for 7/7 genes
(swirl, snailhouse, somitabun, minifin, silberblick, pipe-
tail, and lost-a-fin), while Nasevicius and Ekker (2000)
report a 100% success rate for all nine genes studied
(including no tail, chordin, one-eyed-pinhead, nacre, and
sparse). This provides very substantial encouragement for
pursuing this antisense approach.
However, these data also highlight several characteristics
of morpholino-induced phenotypes, most importantly, the
variability of the severity of the phenotypes and the non-
specific side effects caused by oligo injection.
Variability in the Severity of Phenotypes
An important consideration in the use of morpholinos is
the extent to which they give consistent results when one
dose is injected into a group of embryos. Importantly,
injections of a morpholino complementary to GFP mRNA
reduced GFP protein expression in all cells of fish express-
ing a GFP transgene, indicating that, at least in this case,
the morpholino spread evenly throughout the zebrafish
embryo after injection (Nasevicius and Ekker, 2000). In
some cases, extremely consistent results have been re-
ported for oligo effectiveness. For example, a bmp7 oligo
causes extreme dorsalization at final concentrations of 1
and 4 M in 81 and 93% of cases, respectively (Imai and
Talbot, 2001). A 5.4 M final concentration of chordin oligo
phenocopies the chordin null mutant embryo in more than
75% of cases (Nasevicius and Ekker, 2000), and no tail is
phenocopied in 98% (Nasevicius and Ekker, 2000; using
10.8 M) and 100% of cases (Feldman and Stemple, 2001;
using 2.1–8.6 M final concentration). For no tail, this
correlates with a complete lack of protein on a Western blot
(Nasevicius and Ekker, 2000).
TABLE 1
Genetic mutant Reference
swirl, snailhouse, somitabun,
minifin, silberblick, pipetail
Lele et al., 2001
no tail, chordin, one-eyed-
pinhead, nacre, sparse
Nasevicius and Ekker, 2000
cyclops Karlen and Rebagliati, 2001
snailhouse, swirl Imai and Talbot, 2001
squint, one-eyed pinhead, notail Feldman and Stemple, 2001
sucker/edn1 Miller and Kimmel, 2001
colourless Dutton et al., 2001
lost-a-fin Bauer et al., 2001
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For other targets, the results are much more variable.
Smad 5 depletions, caused by a 6.5-ng dose, giving a final
concentration of 7.8 M, resulted in 24% of embryos with
a weak phenotype compared with the genetic mutant,
somitabun, while 49% resembled the mutant and 27% had
stronger effects (Lele et al., 2001). Higher doses than 6.5 ng
caused nonspecific effects. One-eyed-pinhead morpholino-
injected embryos showed the expected phenotype in only
43% of cases (10.8 M), and the rest of the embryos were
normal (Nasevicius and Ekker, 2000). Thus, the potential
variability in penetrance of the morpholino is an important
consideration for interpreting data. While, in some in-
stances, a graded series of phenotypes equivalent to an
allelic series may be very beneficial for functional analyses,
when novel genes are being studied, it may add to the
uncertainty of what is real and what is a nonspecific side
effect. This will be particularly true if the toxic dose is close
to the effective dose.
A second variability to keep in mind when comparing
morpholino-induced mutant phenotypes and genetic muta-
tions, is that the morpholino derived mutant might lie
anywhere on the entire spectrum of phenotypes caused by
complete depletion of protein to only a slight reduction in
protein levels. The degree of depletion will depend on many
parameters, as well as oligo concentration, including the
amount and stability of the protein that is present at the
time of oligo introduction, the amount of diffusion, the
localization of the targeted mRNA, and the amount of new
transcription. In making meaningful comparisons with ge-
netic phenotypes, it is also helpful to compare the morpho-
lino phenotype with both null mutations and hypomorphic
mutations. It is clearly possible for morpholinos to cause
more severe phenotypes than hypomorphs, or null alleles
that only affect zygotic gene products (e.g., Bauer et al.,
2001).
Side Effects of Morpholino Oligos
Since morpholino oligos were developed for delivery by
scrape-loading into cells in tissue culture, no guidelines
suitable for embryo injection were commercially available.
Thus, researchers routinely injected a series of increasing
doses of oligo into zebrafish embryos and examined them
for both expected and unexpected phenotypes. In typical
experiments, 1 nl of a range of concentration of oligo
(0.1–0.8 mM; with a final concentration of 1–8 M) was
injected into the yolk of genetically wild-type embryos at
the one-cell stage. Several authors report that, at the high
end of this range, nonspecific effects occur. These include
widespread cell death (Braat et al., 2001; Lele et al., 2001),
defects in epiboly, (Imai and Talbot, 2001), and neural
degeneration (Nasevicius and Ekker, 2000; Karlen and Re-
bagliati, 2001), effects that would not be expected from
genetic mutants in which the genes are completely inacti-
vated.
Why morpholinos cause side effects is a major question
that remains to be resolved. Clearly, the likely possibilities
are either that there are nonspecific effects of morpholino
oligos or contaminants, or that there are effects due to
unexpected complementarity of the oligo to other unknown
genes. The appearance of these effects is highly oligo-
dependent. For example, two groups compared the deple-
tion of bmp2b protein using different morpholinos. One
oligo, complementary to 61 to 37 of the 5UTR of
bmp2b sequence caused the specific dorsalized swirl phe-
notype in 80% of cases at final concentrations of 0.4 M,
but caused nonspecific epiboly defects and lysis when 1 M
was injected (Imai and Talbot, 2001). In contrast, a second
oligo, designed against 4 to 19, phenocopied the swirl
mutant at 3.8 M, and only caused cell death at doses
higher than this (Lele et al., 2001). This difference is not due
to variability in calibrating the dose used, since both groups
also targeted bmp7, this time using the same oligo and
having comparable results.
Since it has not been resolved whether side effects are
nonspecific or due to the morpholino being complementary
to an unknown target, controls for both possibilities are
incorporated into most published work (see below).
Oligo Stability
Since morpholino oligos are DNA analogs, they are not
susceptible to enzymatic degradation (Hudziak et al., 1996),
unlike DNA oligos, and thus have much higher biological
stability. This makes it feasible to target genes expressed
during organogenesis by injecting oligos into the one- to
two-cell-stage embryo. In the case of the vasa gene, its
protein could not be detected by confocal microscopy 4 days
after the initial injection of 12 M final concentration (1 ng)
of morpholino oligo (Braat et al., 2001). Nasevicius and
Ekker (2000), studying the loss of body pigmentation with a
nacre morpholino, noted nearly complete loss of pigment
through 2 days of development. Similarly, morpholino-
injected embryos phenocopied the colourless mutant in
having reduced melanophores after 48 h of development.
Here, the oligo-derived mutants were never as complete as
the strongest cls mutants, since some melanophores were
always present (Dutton et al., 2001).
Presumably, oligos eventually lose effectiveness by dilu-
tion. Clearly, the length of the loss-of-function effect of an
injected oligo depends on the transcription and translation
characteristics of the targeted mRNA, as well as the dose of
oligo, and will need to be determined for each gene of
interest.
How Widely Applicable Are Morpholino Oligos?
Morpholinos have been used in several model organisms
in loss-of-function studies. In Xenopus, we have routinely
used DNA oligos to study maternal gene function, and
have, in several cases, compared the effectiveness of mor-
pholinos and DNA oligos. We find there are clear advan-
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tages and disadvantages of both approaches. DNA oligos’
efficacy can be very easily measured, by comparing the
amount of RNA left in control and experimental oocytes
after oligo injection, using either PCR or Northern analysis.
In comparison, morpholinos do not degrade RNA, and their
activity needs to be confirmed in other ways, generally by
Western blotting or immunostaining, and antibodies are
not always available. Another approach to show their
activity is to inject a GFP-tagged version of the mRNA and
to show that the oligo reduces GFP fluorescence (Yang et
al., 2001). One limitation of this is, however, that the
endogenous mRNA and injected version may not have the
same accessibility to the morpholino, and so this control
does not guarantee that the oligo will have the same effect
on the endogenous mRNA.
A clear advantage of morpholinos is that they can be
injected directly into fertilized eggs without the toxic
effects associated with DNA oligos. For example, when a
morpholino oligo against the Wnt pathway component, 
catenin, was injected at the two-cell stage, it caused com-
plete loss of axial structures, mimicking the effect of a
phosphorodiester/phosphorothioate oligo injected into the
oocyte (Heasman et al., 2000). The effective dose in this
case (5–10 ng; 0.6–1.2 M final concentration) is very
similar to the typical doses used in zebrafish studies. Thus,
as long as there is no stored pool of protein, morpholinos
can effectively block maternal gene function.
Another perceived advantage of morpholinos is that,
since they only work by targeting the start site of the
mRNA, it is easier to design an effective oligo. For DNA
oligos, five or six oligos are typically tested to find the most
efficient one. However, morpholino oligos cannot simply be
assumed to be consistently effective. In those cases where
more than one oligo has been designed to be complemen-
tary to different parts of the 5UTR sequence of a target
mRNA, the oligos have had different degrees of effective-
ness in blocking translation (Imai and Talbot, 2001; Lele et
al., 2001). This suggests that, as for DNA oligos, we are
ignorant of many of the variables underlying morpholino
activity.
As in zebrafish studies, it is clear that morpholino oligos
may cause side effects in Xenopus, and that as the dose
increases, the possibility of nonspecific abnormalities also
rises. Thus, it is not possible to rely solely upon a dose
response for revealing a specific phenotype (Audic et al.,
2001). Abnormalities include anterior/posterior trunca-
tions, microcephaly, (Nutt et al., 2001), slowed cleavage,
delayed development, and widespread cell death (unpub-
lished observations). In some cases, the toxic dose can be
clearly distinguished from the effective dose. Nutt et al.
(2001) found that 1 ng (1.2 M final concentration) of
morpholino against GFP caused complete inhibition of GFP
fluorescence in transgenic embryos carrying an integration
of the CMV-GFP transgene, while 40 ng (4.8 M final
concentration) was injected to cause 45% of the embryos to
develop abnormally. In other cases, specific and nonspecific
effects can only be distinguished by the use of appropriate
controls.
One type of control frequently used both in Xenopus and
zebrafish studies is to inject other morpholino oligos, either
a nonsense morpholino oligo, an invert of the antisense
oligo or a mismatched oligo. These cannot control for the
possibility that the experimental oligo is binding to an
unexpected mRNA, since they do not have the same
sequence. An even worse control is to use the sense oligo,
since this should clearly bind to the antisense oligo and
block its activity, whether or not that activity is specific.
Thus, these types of controls only control for nonspecific
toxic contaminants (if they were synthesized at the same
time and with the same reagents, machine, and personnel
as the experimental oligo).
For DNA antisense oligos, that act by degrading mRNA,
specificity can be tested directly, by injecting synthetic
mRNA into oocytes after the endogenous mRNA has been
degraded by the oligo, and testing its ability to rescue the
phenotype. A similar control is necessary for morpholino
experiments. However, if the injected mRNA has the 5
sequence complementary to the oligo, it will bind to the
oligo and prevent its activity directly, by competing for
binding to the endogenous mRNA. This is not a good
control for specificity. A better control is to use an mRNA
that either lacks the 5 UTR recognized by the oligo
(Heasman et al., 2000; Nasevicius and Ekker 2000; Bauer et
al., 2001; Satou et al., 2001), or has third base modifications,
so that it is no longer recognized by the oligo (Cui et al.,
2001). Unfortunately, rescue experiments are often plagued
themselves with complications due to the incorrect distri-
bution and activity of the injected mRNA (Sumanas et al.,
2001). An alternative approach may be to use two different
morpholino oligos to target the mRNA (Howard et al.,
2001; Sumanas et al., 2001), and ask if they cause the same
phenotype.
Another consideration specific to X. laevis is that its
allotetraploidy means there are often two orthologs of the
gene of interest. These are generally very similar in the
coding sequence, but have significant differences in the
5UTR. So, to target both orthologs, morpholinos have to be
designed either to complement the conserved coding region
at the start site, or two oligos need to be made (Sumanas and
Ekker, 2001). The related frog, Xenopus tropicalis, has a
diploid genome, and is also amenable to morpholinos (Nutt
et al., 2001) and thus may become a more popular model
than X. laevis for morpholino studies.
Morpholinos have also been tested in ascidian (Satou et
al., 2001) and mouse oocytes (Coonrod et al., 2001), and
shown to phenocopy the expected phenotypes for loss-of-
function of the  catenin and mos genes, respectively. In
both sea urchin and chick embryos, morpholinos have been
used to study novel gene function, and in each case, several
lines of evidence, as well as the morpholino data were
presented to confirm the conclusions (Howard et al., 2001;
Kos et al., 2001). Thus, for organisms that have typically
lagged behind the genetic model organisms in loss-of-
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function assays, morpholinos offer a welcome additional
approach.
CONCLUSIONS
In recent months, research on morpholinos has moved
beyond the testing phase to the study of novel gene func-
tion. Because morpholinos do cause variable side effects and
do have variable penetrance, embryos injected with mor-
pholinos may have phenotypes that are difficult to inter-
pret. The loss-of-function effects of morpholinos have to be
supported by control mRNA rescue experiments, or, if
those experiments are inconclusive, (e.g., because the in-
jected mRNA has pleiotropic effects), by evidence that two
morpholinos complementary to different parts of the
5UTR have the same effect, or by evidence from other
overexpression and/or underexpression studies (Ross et al.,
2001; Shepherd et al., 2001). In a recent study, for example,
two morpholino oligos directed against the zebrafish type 1
serine/threonine kinase receptor Alk8, caused a dorsalized
phenotype. This was partially rescued by an injected
mRNA lacking the 5UTR sequence targeted by the mor-
pholinos. The authors went on to show that Alk 8 is
disrupted in partially dorsalized lost-a-fin mutants, and that
the mutant is also rescued by Alk8 mRNA, but not by
mRNA for BMPs2 b or 7 (Bauer et al., 2001). Together, the
data prove the requirement for Alk 8 in the BMP-signaling
pathway in zebrafish.
A second example of the use of morpholinos is described
by Deardorff et al. (2001). A morpholino directed against a
Xenopus Wnt receptor Xfz3 was used to test the role of Xfz3
in neural crest formation. The effectiveness of the oligo in
blocking translation was shown by Western blotting with
an Xfz3-specific antibody. Its ability to block signal trans-
duction was tested in explant assays, by comparing the
up-regulation of Xslug by Xwnt 1, in the presence or
absence of the MO. The effect of the morpholino oligo was
then tested in whole embryos by injecting the oligo into
cells fated to form neural crest, i.e., dorsal animal cells at
the 32-cell stage. The oligo inhibited neural crest formation
and this was rescued by coinjection with mouse Xfz3
mRNA (Deardorff et al., 2001).
In both these cases, the phenotype seen with the morpho-
lino oligo was supported by other approaches, and there
were clear expectations that guided the analysis. Far more
challenging will be the use of morpholinos to study com-
pletely novel gene function, where there are no clues to
distinguish real from nonspecific phenotypes. It will be
necessary to have the complete open reading frame of the
targeted gene in order to carry out rescue experiments.
In summary, morpholinos have had substantial testing in
embryos. As with most injection experiments, they may
cause side effects, and may cause an array of phenotypes
that require careful interpretation. These drawbacks can be
overcome by a variety of controls and by comparison with
other loss- and gain-of-function results. The most impor-
tant technical question to answer in their development is
why higher doses of biologically inert morpholinos should
have side effects. But, with cautious use and clear controls,
morpholinos will certainly speed the flow of developmental
gene function data.
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